Versus Abiraterone(与阿比特龙对比)研究综述
Versus Abiraterone 与阿比特龙对比 - This decision was triggered by the results of a safety interim analysis of ERA-223, a trial investigating the combination of radium-223 and abiraterone versus abiraterone alone in patients without prior chemotherapy (with the exception of adjuvant treatment) with asymptomatic bone predominant mCRPC. [1] This decision was triggered by the results of a safety interim analysis of ERA-223, a trial investigating the combination of 223Ra and abiraterone versus abiraterone alone in patients without prior chemotherapy (with the exception of adjuvant treatment) with asymptomatic bone predominant mCRPC. [2] In an exploratory analysis of mCRPC patients receiving first-line therapies, a significant interaction was observed between plasma AR and docetaxel versus abiraterone/enzalutamide for OS (HR = 0. [3]这一决定是由 ERA-223 的安全性中期分析结果触发的，该试验研究了镭 223 和阿比特龙的组合与阿比特龙在没有先前化疗（辅助治疗除外）的无症状骨主要 mCRPC 患者中的比较。 [1] 这一决定是由 ERA-223 的安全性中期分析结果触发的，该试验研究了 223Ra 和阿比特龙的组合与阿比特龙在没有先前化疗（辅助治疗除外）的无症状骨主要 mCRPC 患者中的组合。 [2] 在对接受一线治疗的 mCRPC 患者的探索性分析中，观察到血浆 AR 和多西他赛与阿比特龙/恩杂鲁胺之间的显着交互作用（HR = 0. [3]
Abiraterone Versus Abiraterone 阿比特龙与阿比特龙
This decision was triggered by the results of a safety interim analysis of ERA-223, a trial investigating the combination of radium-223 and abiraterone versus abiraterone alone in patients without prior chemotherapy (with the exception of adjuvant treatment) with asymptomatic bone predominant mCRPC. [1] This decision was triggered by the results of a safety interim analysis of ERA-223, a trial investigating the combination of 223Ra and abiraterone versus abiraterone alone in patients without prior chemotherapy (with the exception of adjuvant treatment) with asymptomatic bone predominant mCRPC. [2]这一决定是由 ERA-223 的安全性中期分析结果触发的，该试验研究了镭 223 和阿比特龙的组合与阿比特龙在没有先前化疗（辅助治疗除外）的无症状骨主要 mCRPC 患者中的比较。 [1] 这一决定是由 ERA-223 的安全性中期分析结果触发的，该试验研究了 223Ra 和阿比特龙的组合与阿比特龙在没有先前化疗（辅助治疗除外）的无症状骨主要 mCRPC 患者中的组合。 [2]
versus abiraterone alone 与单独使用阿比特龙
This decision was triggered by the results of a safety interim analysis of ERA-223, a trial investigating the combination of radium-223 and abiraterone versus abiraterone alone in patients without prior chemotherapy (with the exception of adjuvant treatment) with asymptomatic bone predominant mCRPC. [1] This decision was triggered by the results of a safety interim analysis of ERA-223, a trial investigating the combination of 223Ra and abiraterone versus abiraterone alone in patients without prior chemotherapy (with the exception of adjuvant treatment) with asymptomatic bone predominant mCRPC. [2]这一决定是由 ERA-223 的安全性中期分析结果触发的，该试验研究了镭 223 和阿比特龙的组合与阿比特龙在没有先前化疗（辅助治疗除外）的无症状骨主要 mCRPC 患者中的比较。 [1] 这一决定是由 ERA-223 的安全性中期分析结果触发的，该试验研究了 223Ra 和阿比特龙的组合与阿比特龙在没有先前化疗（辅助治疗除外）的无症状骨主要 mCRPC 患者中的组合。 [2]